KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: A report from the Children's Oncology Group

Amy K. Erbe, Mitch B. Diccianni, Rajen Mody, Arlene Naranjo, Fan F. Zhang, Jen Birstler, Kyungmann Kim, Arika S. Feils, Jung Tung Hung, Wendy B. London, Barry L. Shulkin, Varsha Mathew, Marguerite T. Parisi, Sabah Servaes, Shahab Asgharzadeh, John M. Maris, Julie Park, Alice L. Yu, Paul M. Sondel, Rochelle Bagatell